CME: 4 Things to know about CKD and SGLT2i

Overview
For a long time, there were no new developments in the field of chronic kidney disease (CKD), despite the huge burden of this disease with a high morbidity and mortality rate. During the last few years, results of the first dedicated kidney trials with SGLT2 inhibitors –CREDENCE, DAPA-CKD and EMPA-KIDNEY– were presented and published. They show beneficial effects of SGLT2 inhibitors in patients with CKD and as a result the KDIGO guidelines were updated in 2022 to include this new evidence.
Four speakers go through the evidence of these trials, and how to implement the findings into clinical practice. Furthermore, they outline the current situation of prescription of SGLT2 inhibitors in nephrology, and inform us about the role of primary care in this field.
This course consists of 4 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
Program Highlights
This educational program consists of four presentations on CKD and SGLT2 inhibitors.
What is the evidence of SGLT2i in CKD? - Hiddo L. Heerspink, PhD – Groningen, The Netherlands
- Prof. Heerspink explains in this video that SGLT2i slow the progression of CKD, and reduce the risk of kidney failure and acute kidney injury.
When and how to initiate SGLT2i in CKD - David Wheeler, MD – London, UK
- Prof. Wheeler illustrates which patients with CKD should be treated with SGLT2 inhibitors using three case studies.
A call to action: optimizing treatment in CKD - Meg Jardine, MD, PhD – Sydney, Australia
- To what extent does the evidence of RCTs on use of SGLT2i in patients with CKD translate to clinical practice? Meg Jardine gives an overview of studies and provides tools to increase uptake of SGLT2i in this field.
Primary care role in CKD - Richard Hobbs, MD - Oxford, UK
- Prof. Hobbs talks about how to diagnose CKD and explains when to refer patients with CKD from primary care.
Instructions
- Watch the three lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate
For questions regarding this activity, please contact us at info@pace-cme.org.
Learning Objectives
- Discuss results of kidney outcomes trials with SGLT2 inhibitors
- Recall what to take into account when initiating SGLT2 inhibitors
- Illustrate the situation of current prescription of SGLT2 inhibitors by nephrologists
- Describe the role of primary care in CKD
Target Audience
This educational activity is designed for all healthcare professionals with an interest in management of patients with CKD.
Accreditation and Credit Designation Statements
This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Commercial Support
Funding for this educational program was provided by an unrestricted educational grant received from AstraZeneca.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 06/04/2023
Expiration Date: 06/04/2025

Hiddo L. Heerspink, PhD

David Wheeler, MB, CHB, MD, FRCP

Meg Jardine, MD, PhD

Richard Hobbs, MD

Title

Share on ReachMD